SUPN - Company ID 0001356576
The table below shows SUPERNUS PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M | $520.40M |
| Cost of revenue | $74.56M | $77.91M | $83.78M | $87.22M | - | $52.46M |
| Gross profit | - | - | - | - | - | - |
| R&D | $106.23M | $108.80M | $91.59M | $74.55M | $90.47M | $75.96M |
SUPERNUS PHARMACEUTICALS, INC. reported annual revenue of $718.95M for fiscal year 2025. That is up 8.6% from $661.82M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $215.00M (FY 2016) to $718.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $485.56M |
| $321.58M |
| $336.36M |
| $377.22M |
| $304.76M |
| $200.68M |
| Operating income | -$62.28M | $81.67M | -$5.27M | $46.12M | $86.03M | $173.70M |
| Income tax | -$10.48M | $24.00M | $1.45M | $32.00K | $19.75M | $41.70M |
| Net income | -$38.60M | $73.90M | $1.30M | $60.70M | $53.40M | $126.95M |
| EPS (diluted) | -$0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 |